Poor
Not Aligned
Patient Risk:
Low
Summary
The provided claims are largely generic statements about clinical programs/graphical presentation and do not address the supplied on-label section about blood pressure increases. As evaluated only against the provided prescribing information excerpt (5.4/6.1/7.4/17), none of the graph/endpoint/patient-interest statements are supported; the only potentially label-linked item is that JATENZO can increase blood pressure, which is not among the user's claims list.
Category Scores
Accurate Statements
Jatenzo is an oral testosterone undecanoate product.
Not supported or verifiable from the supplied label excerpt (5.4/6.1/7.4/17).
Unsupported Statements
Approval of Jatenzo relied on clinical evidence evaluating how well it raises and maintains testosterone levels in men with hypogonadism.
The supplied prescribing information excerpt does not describe the approval basis or efficacy endpoint/indication details.
The Jatenzo clinical program includes controlled studies that compare testosterone levels over time.
No controlled-study description or testosterone over-time comparisons are included in the provided excerpt.
The clinical program uses graph-style endpoints, such as testosterone concentration versus time, to show treatment effect.
The excerpt does not mention testosterone concentration vs time endpoints or “graph-style endpoints.”
Prescribing information for Jatenzo often includes key visual data such as testosterone changes over time.
The excerpt does not discuss visual data or testosterone change graphics.
Jatenzo summary graphs typically plot total testosterone (or calculated testosterone) versus time after dosing.
No “summary graphs” or testosterone plotting details are present in the excerpt.
Jatenzo summary graphs typically plot the proportion or percentage of patients achieving target testosterone ranges.
The excerpt does not mention target testosterone ranges or proportions achieving targets.
Jatenzo summary graphs typically plot dose adjustments or maintenance patterns over a treatment period.
The excerpt does not describe dosing adjustment graphs or maintenance patterns.
Jatenzo effectiveness graphics generally focus on testosterone concentration over time and whether patients maintain levels consistent with normal physiologic ranges.
No effectiveness graphics or physiologic-range maintenance statements appear in the excerpt.
Trial reports commonly summarize how many participants reach target concentrations and how stable levels are across the study duration.
The excerpt does not discuss target concentrations, stability, or participant reach rates.
Users typically want to understand how quickly testosterone levels rise after starting Jatenzo.
Patient/UX intent is not addressed in the supplied prescribing information excerpt.
Users typically want to understand how much variability exists between patients on Jatenzo.
Variability between patients is not addressed in the supplied excerpt.
Users typically want to understand whether testosterone stays controlled at steady dosing with Jatenzo.
Steady dosing/testosterone control discussions are not in the supplied excerpt.
Users typically want to know how often adverse events occur and whether there are lab trends linked to testosterone changes with Jatenzo.
The excerpt does not provide adverse event frequency summaries overall or link lab trends to testosterone changes.
The side-effect frequency data referenced as coming from the study documentation is presented in separate tables.
The excerpt does not describe the structure or presentation format of adverse event frequency data.
Contradictions
Important Omissions
None of the claims directly covered the provided-on-label blood pressure warning/precaution content (e.g., that JATENZO can increase BP; ABPM mean changes; recommendation for periodic BP monitoring; not recommended in uncontrolled hypertension; additional BP increase risk with concomitant BP-increasing medications).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are mostly about clinical evidence presentation and user intent, not direct medical instructions or contraindications. However, they do not accurately reflect the supplied label’s blood pressure warning content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are unsupported by the provided FDA label excerpt (5.4/6.1/7.4/17) and concern testosterone endpoint/graphing topics not contained in the supplied text.
Suggested Improvement
Limit claims to what is explicitly present in the provided prescribing information excerpt, particularly the blood pressure increase warning (5.4) and related ABPM clinical trial findings (6.1), plus the monitoring and concomitant BP-increasing medications counseling (5.4/7.4/17).